Built Biotechnologies: Pioneering DNA Manufacturing Breakthroughs

In a significant step forward for synthetic biology, TeselaGen is spinning off a new initiative called Built Biotechnologies. The primary focus of this new venture is addressing critical issues in DNA manufacturing, with a particular emphasis on the construction of long and complex DNA molecules.

Solving DNA Manufacturing Problems with Built Biotechnologies

Built Biotechnologies is set to address several critical problems that currently plague DNA manufacturing. Arguably, their most significant contribution is the ability to routinely construct complex DNA molecules, which are often challenging to build but are required for the advancement of mammalian and plant synthetic biology. George McArthur, the Senior Director of Experience at TeselaGen, stated that a significant number of cell and gene therapy candidates remain untested simply because the necessary DNA constructs are too difficult to establish using known methods. Built Biotechnologies aims to meet these unmet needs and more.

The Strategic Location of Built’s State-Of-The-Art Laboratory

The first state-of-the-art laboratory for Built is positioned strategically in Charlottesville, VA. This location has been chosen for its easy access to numerous biotechnology and life science institutions on the East Coast, thereby encouraging collaboration and fostering an environment of innovation.

Collaboration between TeselaGen and Built Biotechnologies

As part of the strategic initiative, TeselaGen will work closely with Built, enabling direct access to an experimental facility. This facility permits TeselaGen to further test, augment, and validate its computational models. The close collaboration is anticipated to foster advancements in crucial areas and set new benchmarks for success and innovation in biotechnology.

In conclusion, the establishment of Built Biotechnologies marks a significant leap in TeselaGen’s ongoing efforts to advance synthetic biology and its real-world applications. This initiative promises to revolutionize DNA manufacturing and significantly impact the biotech industry.

Don’t miss our latest Startup News: Boosting Security: Palo Alto Networks Acquires Dig Security

Exit mobile version